Drag

Marksans Pharma Limited

Healthcare MARKSANS

177.58INR
-2.46 ( -1.37%)

Last update at

Day Range

173.88181.44
LowHigh

52 Week Range

162.00 275.43
LowHigh

Fundamentals

  • Previous Close 180.04
  • Market Cap 81052.87M
  • Volume616,747
  • P/E Ratio 23.02
  • EBITDA 4706.42M
  • Revenue TTM 27307.02M
  • Revenue Per Share TTM 60.24
  • Gross Profit TTM 14823.68M
  • Diluted EPS TTM 7.77

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Total Revenue
Net Income

Balance Sheet

Total Assets
Total Liabilities

Change in Cash

Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Income before tax 5039.67M 4235.26M 3376.53M 2475.11M 3021.64M
Net income 3805.75M 3137.00M 2653.21M 1868.14M 2385.39M
Total Revenue 26228.45M 21774.07M 18521.39M 14801.24M 13683.73M
Gross Profit 14791.03M 11033.60M 9307.81M 7321.08M 7497.77M
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Total assets 32396.32M 26809.53M 21903.89M 16401.00M 12282.51M
Intangible assets 727.32M 647.62M 707.97M 585.69M 474.36M
Other current assets 1114.67M 853.96M 526.43M 185.05M 118.25M
Deferred long term liab - - - - -
Non current assets other - - - - -
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Change in Cash 925.09M 208.40M 1760.31M 1370.82M 1185.59M
Operating Cash 2066.64M 2304.07M 2374.12M 992.57M 1787.41M
Free Cash Flow 337.45M 215.69M 1837.81M 529.27M 1323.17M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - General

Company Change Price Market Cap (M) P/E Ratio
MARKSANS
Marksans Pharma Limited 		-2.46 -1.37% 177.58 81052.87 23.02
GLAXO
GlaxoSmithKline Pharmaceuticals Limited 		-22.40 -0.92% 2412.90 406354.23 42.58
PFIZER
Pfizer Limited 		83.80 1.80% 4751.40 222237.90 26.50
SANOFICONR
SANOFI CONS HEALTHC IND L 		-97.90 -2.23% 4291.00 101612.67 46.61
SANOFI
Sanofi India Limited 		22.40 0.56% 4037.60 95811.08 26.88

Profile

Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeutic areas. Its product portfolio includes plain, enteric-coated, and film coated tablets; soft gelatin and hard capsules; oral liquids; and ointments, as well as creams and liquids. The company provides its products to supermarkets, high street retailers, pharmacy chains, and wholesalers. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.

Marksans Pharma Limited

Grandeur, Mumbai, India, 400053

Key Executives

Name Title Year Born
Mr. Mark B. Saldanha Non-Independent Exec. Chairman, MD & CEO 1972
Mr. Jitendra M. Sharma Chief Financial Officer 1969
Mr. Anjani Kumar Chief Operating Officer - Global Operations 1960
Mr. Harshavardhan Panigrahi Company Sec., Mang. of Legal & Compliance Officer NA
Mr. Sunil K. Rane Sr. VP of QC 1969
Mr. Sopan Pisal Director of QA 1971
Mr. Supratika Tripathi Director of Operations 1960
Mr. Sridhar Naidu Gen. Mang. of HR & Admin 1979
Mr. Umesh Rivankar Head of Domestic Marketing NA
Mr. David Mohammed Managing Director of Nova Pharmaceuticals Australasia Pty Ltd NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data ("EODHD") on an 'as is' basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.